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ABSTRACT
Objectives To compare cognitive effects and 
acceptability of repetitive transcranial magnetic 
stimulation (rTMS) and transcranial direct current 
stimulation (tDCS) in patients with Alzheimer’s disease 
(AD) or mild cognitive impairment (MCI), and to 
determine whether cognitive training (CT) during rTMS or 
tDCS provides additional benefits.
Methods Electronic search of PubMed, Medline, 
Embase, the Cochrane Library and PsycINFO up to 5 
March 2020. We enrolled double- blind, randomised 
controlled trials (RCTs). The primary outcomes were 
acceptability and pre–post treatment changes in general 
cognition measured by Mini- Mental State Examination, 
and the secondary outcomes were memory function, 
verbal fluency, working memory and executive function. 
Durability of cognitive benefits (1, 2 and ≥3 months) 
after brain stimulation was examined.
Results We included 27 RCTs (n=1070), and the 
treatment components included high- frequency rTMS 
(HFrTMS) and low- frequency rTMS, anodal tDCS (atDCS) 
and cathodal tDCS (ctDCS), CT, sham CT and sham brain 
stimulation. Risk of bias of evidence in each domain was 
low (range: 0%–11.1%). HFrTMS (1.08, 9, 0.35–1.80) 
and atDCS (0.56, 0.03–1.09) had short- term positive 
effects on general cognition. CT might be associated 
with negative effects on general cognition (−0.79, –2.06 
to 0.48) during rTMS or tDCS. At 1- month follow- up, 
HFrTMS (1.65, 0.77–2.54) and ctDCS (2.57, 0.20–4.95) 
exhibited larger therapeutic responses. Separate analysis 
of populations with pure AD and MCI revealed positive 
effects only in individuals with AD. rTMS and tDCS were 
well tolerated.
Conclusions HFrTMS is more effective than atDCS for 
improving global cognition, and patients with AD may 
have better responses to rTMS and tDCS than MCI.
INTRODUCTION
Alzheimer’s disease (AD) and mild cognitive impair-
ment (MCI) are substantial healthcare challenges 
in the 21st century.1 The treatment of cognitive 
decline is key to managing AD and MCI1; however, 
pharmacological interventions provide suboptimal 
benefits for AD and exhibit no effects on MCI, 
and curative or disease- modifying therapies are 
currently lacking.1 Accumulating evidence suggests 
that non- invasive electrical brain stimulation (NIBS) 
may be effective alternative treatments.2
Repetitive transcranial magnetic stimulation 
(rTMS) and transcranial direct current stimulation 
(tDCS) are the two most widely investigated NIBS 
interventions.2 3 rTMS is applied to the scalp using 
a coil, and uses strong but brief electromagnetic 
pulses to modify underlying brain activity. Usually, 
rTMS is considered excitatory when using high- 
frequency (HF) protocols (≥10 Hz) or intermit-
tent theta- burst stimulation, and inhibitory when 
using low- frequency (LF) (≤1 Hz) protocols or 
continuous theta- burst stimulation.4 In contrast, in 
tDCS, a low- intensity electric current (usually 1–2 
mA) is injected into the brain through electrodes 
placed over the scalp. Electrons flow from the 
cathode to the anode, in the radial direction. The 
electric current does not generate action potentials 
per se, but facilitates or inhibits synaptic transmis-
sion; this is mediated by an increase or decrease in 
the frequency of action potentials in endogenous 
neuronal firing, usually induced by anodal or cath-
odal stimulation, respectively.5 Although clinical 
protocols are highly variable, tDCS and rTMS are 
generally applied daily for 20–40 min, over a period 
of 2–5 weeks.6 Both techniques have proven safety 
and tolerability, do not require sedation or anaes-
thesia, and have few contraindications.6 Although 
rTMS presents a low risk of seizures, the risk can be 
almost mitigated by adherence to published proto-
cols.7 Clinical application of rTMS, including as a 
treatment for major depression, is more widespread 
compared with the use of tDCS.8–10 Conversely, 
tDCS is cheaper than rTMS, is portable and is 
relatively easy to use, making home- use of tDCS 
possible.11
Although the mechanisms of action of NIBS tech-
niques remain elusive, both seem to induce long- term 
potentiation and depotentiation- like phenomena 
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as induction of synaptic strengthening and neurogenesis.12 13 
Anodal tDCS (atDCS) and HFrTMS are considered ‘excitatory’ 
NIBS modalities, whereas cathodal tDCS (ctDCS) and LFrTMS 
are considered inhibitory. Both rTMS and tDCS could enhance 
brain activity in areas that are hypoactive, leading to changes 
in functional outcomes. Indeed, when targeting the dorsolateral 
prefrontal cortex (DLPFC), these techniques were shown to 
enhance working memory,14 and, regarding cognitive enhance-
ment, promising findings have been observed for both tDCS15 
and rTMS.16
Two recent pairwise meta- analyses of randomised controlled 
trials (RCTs) reported that rTMS improved global cognition in 
AD17and MCI.18 Preliminary data on tDCS for MCI5 and AD19 
have also been promising. Several studies have reported positive 
results on cognitive function when combining cognitive training 
(CT) with rTMS.20 21 However, there is also evidence suggesting 
negative effects of tDCS plus CT on cognitive function.22 23 To 
date, an in- depth comparison of the effects of direct rTMS and 
tDCS in RCTs, as well as the effects of CT during rTMS or tDCS 
interventions, is lacking.
In the current study, we used a systematic review and compo-
nent network meta- analysis (NMA) approach to assess the 
cognitive effects and acceptability of different rTMS and tDCS 
modalities in patients with MCI or AD. We sought to investi-
gate the effects of rTMS and tDCS on general cognitive function 
and specific cognitive domains; whether CT provides addi-
tional effects when combined with rTMS or tDCS; whether the 
treatment effects of rTMS and tDCS are sustained, and finally, 
whether some cognitive domains have late onset responses.
METHODS
This study protocol is registered in PROSPERO 
(CRD42018104591). We followed the guidelines of the 
Preferred Reporting Items for Systematic Reviews and Meta- 
Analyses (PRISMA) extension statement for NMA.24
Search strategy
Two investigators (C- SC and C- SL) independently searched 
PubMed, Embase and the Cochrane Library from the inception 
of each through to 5 March 2020. Additional unpublished and 
ongoing trials were identified from  ClinicalTrials. gov. When 
data were unavailable in the articles, we contacted the authors 
to request the unreported data. A search algorithm was devel-
oped and adapted for each database, with no restrictions on 
age, setting, sex, ethnicity, language or publication year. The full 
search strategy with search terms (online supplemental appendix 
1) and PRISMA checklist (online supplemental appendix 2) are 
available in the online supplemental data.
Eligibility criteria
Double- blind RCTs that made comparisons with sham treat-
ment in patients with MCI, probable AD or AD were included. 
The criteria for MCI and AD are compatible with international 
guidelines and are listed in online supplemental table S1. Trials 
with fewer than five treatment sessions were excluded, as they 
would not be considered a therapeutic course for any brain- 
stimulation modality.25 LF was defined as ≤1 Hz, and HF was 
defined as ≥5 Hz.26
Data extraction
Two of the authors (P- TT and T- YC) extracted the data of included 
studies using a prespecified data extraction form. Duplicates 
were electronically removed, and only the most recent/complete 
report was included.
Primary and secondary outcomes
The primary outcomes were treatment efficacy for general 
cognitive function and acceptability. As most of the included 
studies used the Mini- Mental State Examination (MMSE) to 
examine general cognitive function, the treatment efficacy 
of global cognition was based on pre–post changes in MMSE 
scores. If different instruments were used to measure general 
cognitive function, the scores were converted to MMSE scores 
using suggested methods.27 Acceptability referred to all- cause 
discontinuation, defined as premature discontinuation of treat-
ment for any reason.
The secondary outcomes were pre–post changes in memory 
function, verbal fluency, working memory and executive func-
tion. In studies using several cognitive instruments to examine 
the same cognitive subdomain, we selected the most reliable 
instrument.28 For trials with follow- up outcomes, long- lasting 
effects were examined at 1 month, 2 months and ≥3 months 
after the last session of NIBS.
Quality assessment
Two independent authors (T- CY and C- KT) assessed the method-
ological quality of the included trials using the revised Cochrane 
risk of bias (ROB V.2.0) tool.29 In cases of discrepancy, a third 
investigator (C- SC) was consulted to obtain a consensus.
Statistical analysis
Several studies combined CT or sham CT (sham_CT) with NIBS 
interventions; such combination treatments can be considered a 
sum of two component parts. We employed an additive compo-
nent NMA model for the data synthesis. A component NMA 
model is an extension of the standard NMA, which can analyse 
the relative efficacy of specific components or combinations of 
components. Therefore, the effect sizes of CT and sham_CT can 
be calculated when CT or sham_CT is combined with NIBS or 
sham brain stimulation (sham_BS). The current NMA had seven 
components: atDCS, CT, ctDCS, HFrTMS, LFrTMS, sham_BS 
and sham_CT.
Mean differences with 95% CIs were calculated for the 
primary outcomes, and standardised mean differences with 95% 
CIs for the secondary outcomes. For interpretation of effect 
sizes, we followed the rules of classifying <|0.2| as very small, 
|0.2|–|0.5| as small, |0.5|–|0.8| as moderate and >|0.8|as 
large.30 We calculated the relative ranking probabilities of all 
treatments for the target primary and secondary outcomes.
The surface under the cumulative ranking curve (SUCRA) 
indicated the mean rank of each treatment relative to an imagi-
nary intervention that was the best without uncertainty. A larger 
area under the curve indicated a higher rank of treatment benefit 
on cognitive effects.
Potential inconsistencies between direct and indirect evidence 
were examined by the node- splitting method and the design- by- 
treatment model. Publication bias was investigated using Egger’s 
tests and comparison- adjusted funnel plots. Meta- regression 
analyses were conducted to examine potential effect modifiers, 
and the differences in effect sizes between AD and MCI were 
analysed. Finally, we assessed the efficacy of sham rTMS stimu-
lation versus sham tDCS stimulation for the primary outcome as 
an additional proof of transitivity.
The NMA was performed using intention- to- treat anal-
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The study selection process is shown in online supplemental 
figure S1. These 27 RCTs were published between 2011 and 
2019. For the 13 rTMS trials (n=436, AD=375, MCI=61), 
the mean age, percentage of women and MMSE score were 
70.5±4.0 years, 53.1%±16.9% and 21.1±4.2, respectively. For 
the 14 tDCS trials (n=634, AD=250, MCI=384), the mean age, 
percentage of women and MMSE score were 73.3±5.0 years, 
60.5%±14.5% and 21.7±4.3, respectively. The characteristics 
of the included studies are summarised in online supplemental 
table S1).
Network plots of eligible comparisons
Figure 1A illustrates the network of eligible comparisons for the 
short- term effects on general cognitive function. The recruited 
trials generated 10 nodes contributing to 12 pairs of compar-
isons. There were three sham treatments (sham_BS, sham_
BS+CT and sham_BS+sham_CT), and sham_BS was used as the 
common comparator. No study directly compared rTMS with 
tDCS. The network plot of long- lasting effects of NIBS is illus-
trated in figure 1B. The supplementary data show the network 




Figure 2A shows the short- term effects of the 10 treatments on 
general cognitive function. The effect size for each treatment 
was compared with sham_BS, and the mean pre–post MMSE 
changes ranged from 1.08 (95% CI, 0.35 to 1.80) for HFrTMS 
to −1.57 (95% CI, −3.05 to −0.09) for sham_BS+sham_CT. 
Statistical significance was observed for HFrTMS, atDCS and 
sham_BS+sham_CT. Combining CT with HFrTMS and atDCS 
did not result in larger effect sizes than were observed when 
using HFrTMS or atDCS alone. The mean pre–post MMSE 
changes of each component ranged from 1.08 (95% CI, 0.37 to 
1.79) for HFrTMS to −1.13 for sham_CT (95% CI, −2.59 to 
0.33), with statistical significance for HFrTMS and atDCS.
Long-lasting effects at 1-month follow-up
MMSE scores were increased with ctDCS, HFrTMS, 
HFrTMS+CT and atDCS compared with that with sham_BS, 
while changes for HFrTMS+CT and atDCS did not reach statis-
tical significance (figure 2B). Both ctDCS and HFrTMS reached 
statistical significance and had larger effects at this time point. 
As observed for short- term effects, combining CT with HFrTMS 
and atDCS did not have larger effect sizes compared with those 
observed using HFrTMS or atDCS alone. Only ctDCS and 
HFrTMS significantly increased MMSE scores compared with 
those with sham_BS.
Comparison of pure AD and MCI groups
Online supplemental figure S3 illustrates the short- term pre–
post MMSE changes in pure AD and MCI groups. Online 
supplemental appendix figure S4 depicts the long- lasting effects 
at 1- month follow- up. HFrTMS had both short- term (1.50, 
0.61–2.40) and long- lasting (1.71, 0.86–2.56) positive effects 
on the population with AD. None of the treatments or compo-
nents reached statistical significance in the population with MCI. 
Benefits of ctDCS were observed in the population with AD at 
1- month follow- up.
Secondary outcomes
Memory function
HFrTMS was the only treatment and component that signifi-
cantly improved memory function after the last rTMS session, 
with a moderate effect size (figure 3). However, this memory 
improvement did not persist after 1- month follow- up. atDCS was 
the only treatment and component that significantly impaired 
memory function at 1- month follow- up, with a large effect size. 
Figure 1 (A) Network of eligible comparisons for general cognition: short- term effects. (B) Network of eligible comparisons for general cognition: long- 
lasting effects after 1 month. atDCS, anodal transcranial direct current stimulation; ctDCS, cathodal transcranial direct current stimulation; HFrTMS, high- 
frequency repetitive transcranial magnetic stimulation; LFrTMS, low- frequency repetitive transcranial magnetic stimulation; sham_BS, sham brain stimulation; 
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Figure 2 (A) Forest plot of NMA of changes of general cognition: short- term effects. (B) Forest plot of NMA of changes of general cognition: long- lasting 
effects after 1 month. atDCS, anodal transcranial direct current stimulation; BS, brain stimulation; CT, cognitive training; ctDCS, cathodal transcranial direct 
current stimulation; HFrTMS, high- frequency repetitive transcranial magnetic stimulation; LFrTMS, low- frequency repetitive transcranial magnetic stimulation; 
LL, lower limit; MD, mean difference; MMSE, Mini- Mental State Examination; NMA, network meta- analysis; UL, upper limit.
Figure 3 (A) Forest plot of NMA of changes of memory function: short- term effects. (B) Forest plot of NMA of changes of memory function: long- lasting 
effects after 1 month. atDCS, anodal transcranial direct current stimulation; BS, brain stimulation; CT, cognitive training; ctDCS, cathodal transcranial direct 
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Combining CT with HFrTMS or atDCS did not significantly 
increase the effect sizes, and therefore did not provide additional 
effects.
Verbal fluency
Both atDCS and atDCS+CT were significantly associated with 
short- term improvement in verbal fluency, with small effect sizes 
(figure 4). Combining CT with atDCS had a larger effect size 
than atDCS alone, and therefore provided additional effects to 
atDCS on verbal fluency. Considering the effect size for each 
component relative to sham_BS, both CT and atDCS were 
significantly associated with beneficial effects on verbal fluency, 
with small effect sizes. However, at 1- month follow- up, the 
beneficial effects of atDCS and CT were not significant.
Working memory
Later responses on working memory were observed for both 
rTMS and tDCS, as none of the treatments resulted in signif-
icant short- term effects (figure 5). Three treatments (ctDCS, 
HFrTMS+CT and HFrTMS) showed statistically significant 
effects at 1- month follow- up. Combining CT with HFrTMS 
had a larger effect size than HFrTMS alone, and therefore CT 
provided additional effects to HFrTMS on working memory. 
ctDCS, CT and HFrTMS were significantly associated with 
beneficial effects on working memory, with moderate- to- large 
effect sizes, when compared with sham_BS.
Executive function
None of the treatments or components reached statistical signifi-
cance for short- term or long- lasting effects on executive function 
(online supplemental figure S5).
Longer durable effects (2 months and ≥3 months)
Due to the limited number of trials that followed up participants 
for longer than 1 month after the last NIBS session, NMA was not 
conducted to examine longer durable effects. Online supplemental 
table S2 summarises the effect sizes of long- lasting effects for each 
study on the primary and secondary outcomes. The effect sizes 
for each study arm ranged from −0.47 for atDCS+sham_CT in 
general cognitive function to 1.72 for ctDCS in memory function.
SUCRA for short-term and long-lasting effects on outcomes
Figure 6 illustrates the SUCRA of each component’s (a) short- 
term effects and (b) long- lasting effects at 1- month follow- up on 
the primary and secondary outcomes, with sham_BS as reference 
treatment.
For the short- term effects, HFrTMS was ranked as the best 
intervention for general cognitive function, and its effect size 
reached statistical significance. ctDCS was ranked as the best 
intervention for memory function, verbal fluency and working 
memory; however, this effect size did not reach statistical signifi-
cance. CT was ranked as the best intervention for executive func-
tion, although its effect size did not reach statistical significance.
For the long- lasting effects at 1- month follow- up, ctDCS was 
ranked as the best intervention for all primary and secondary 
outcomes, although statistically significant effects were only 
observed for general cognitive function and working memory.
Acceptability, adverse events, and dropout
Both rTMS and tDCS were safe and well tolerated. Of the 27 
studies, 8 reported no adverse events (AEs) on both active arm 
and sham arms, and 6 did not report any AEs during the study 
period. Headaches and scalp pain were the most common AEs 
in rTMS protocols. Scalp burning sensation and tingling were 
common in tDCS protocols. Detailed AEs of the 27 studies are 
summarised in the online supplemental table S3. The dropout 
rates were 5.1% (31/599) and 6.1% (29/471) in the intervention 
and sham treatment groups, respectively; this between- group 
difference was not significant (χ2=0.48, p=0.49).
ROB, inconsistency, publication bias, and sensitivity analysis
Based on the Cochrane ROB criteria, six studies were judged as 
having a high ROB, with random sequence generation being the 
Figure 4 (A) Forest plot of NMA of changes of verbal fluency: short- term effects. (B) Forest plot of NMA of changes of verbal fluency: long- lasting effects 
after 1 month. atDCS, anodal transcranial direct current stimulation; BS, brain stimulation; CT, cognitive training; ctDCS, cathodal transcranial direct current 
stimulation; HFrTMS, high- frequency repetitive transcranial magnetic stimulation; LL, lower limit; NMA, network meta- analysis; SMD, standardised mean 
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most frequent (online supplemental table S4). The high ROB in 
each domain ranged from 0% to 11.1%.
The design- by- treatment interaction model and node- splitting 
method did not detect any inconsistencies in the primary 
outcome (online supplemental table S5). Visual inspection of 
funnel plots and Egger’s tests (online supplemental table S6) did 
not identify any risk of publication bias in the primary outcome. 
Meta- regression analyses did not identify any potential effect 
modifiers (online supplemental tables S6 and S7). Finally, the 
pre–post changes in MMSE scores between sham rTMS and 
sham tDCS stimulation were not significant (online supple-
mental figure S7).
Figure 5 (A) Forest plot of NMA of changes of working memory: short- term effects. (B) Forest plot of NMA of changes of working memory: long- lasting 
effects after 1 month. atDCS, anodal transcranial direct current stimulation; BS, brain stimulation; CT, cognitive training; ctDCS, cathodal transcranial direct 
current stimulation; HFrTMS, high- frequency repetitive transcranial magnetic stimulation; LL, lower limit; NMA, network meta- analysis; SMD, standardised 
mean difference; UL, upper limit.
Figure 6 NMA estimates and SUCRA values. BS, brain stimulation; CT, cognitive training; HFrTMS, high- frequency repetitive transcranial magnetic 
stimulation; LFrTMS, low- frequency repetitive transcranial magnetic stimulation; NMA, network meta- analysis; SUCRA, surface under the cumulative ranking 
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DISCUSSION
We found the following primary outcomes: (1) HFrTMS and 
atDCS had short- term positive effects on general cognitive func-
tion; (2) HFrTMS and ctDCS revealed late larger therapeutic 
responses on general cognitive function; (3) CT did not provide 
additional effects; (4) only populations with pure AD, but not 
populations with MCI, significantly responded to HFrTMS and 
ctDCS based on subgroup analysis; and (5) all NIBS treatments 
were well tolerated.
For the secondary outcomes, we observed that: (1) HFrTMS 
had short- term positive effects on memory function, which were 
absent at 1- month follow- up; (2) atDCS was associated with 
short- term positive effects on verbal fluency, and CT provided 
additional effects; and (3) benefits on working memory were 
only observed in ctDCS and HFrTMS, and CT provided addi-
tional effects to those of HFrTMS.
Our study is the first to demonstrate that HFrTMS may 
have better efficacy for general cognition than atDCS, which is 
consistent with the treatment effects on major depressive disor-
ders.9 Although the reasons underpinning the different effects 
of HFrTMS and atDCS on general cognitive function remain 
unclear, distinct pathophysiological mechanisms may indirectly 
influence our findings. Generally, HFrTMS stimulates gyri imme-
diately under the coil at more localised areas, and directly trig-
gers neuronal firing, whereas atDCS modulates resting neuronal 
membrane potential without neuronal firing, and stimulates less 
focal and more diffuse brain regions.31 HFrTMS and atDCS also 
differ substantially in terms of the effective distribution of the 
electric field on the cortical surface. Relative to rTMS, tDCS 
is more strongly influenced by skull anatomical features, with 
up to 50% of the electric field strength affected. Furthermore, 
the temporal resolution and spatial focality of rTMS are more 
precise than that of tDCS.2 Therefore, rTMS may have been 
more focal in the target areas, resulting in potentiation of local 
and distributed neuromodulatory effects.
The use of combined CT with NIBS is controversial, and 
evidence for an additional positive effect of CT in combination 
with NIBS on cognitive function remains insufficient. Previous 
meta- analyses have shown both positive32 33 and no positive 
effects reported.34 35 However, traditional meta- analyses or 
NMA did not specifically evaluate the cognitive effects of CT 
when combined with NIBS. The present study used component 
NMA, which enabled evaluation of each component’s effect. We 
observed that combining NIBS and CT had no additional posi-
tive effects on global cognition; indeed, the outcomes seemed 
to be poorer. The interaction between NIBS and CT on global 
cognition may be influenced by the complexity of functional 
networks in the human brain, whereby the topology, synchronis-
ability, and other dynamic properties of functional networks are 
strongly affected by small- worldness and other metrics of struc-
tural connectivity.36 Patients with AD and MCI exhibit brain 
network dysfunction at both structural and functional levels; 
thus, the combination of NIBS and CT may not exert synergis-
tically beneficial effects on global cognition. Other confounding 
factors may influence the protective effects of NIBS on cognition, 
such as heterogeneity of participants’ characteristics, selection of 
targeted brain regions, and standard CT or tailored/individual-
ised CT. Although we did not identify potential effect modifiers 
based on meta- regression analyses, it is well established that CT 
is more effective at the earliest stage of AD.
With regards to cognition subdomain, we detected addi-
tional effects of CT on working memory and verbal fluency 
when combined with HFrTMS and atDCS, respectively. These 
findings were mainly derived from studies of HFrTMS37 and 
atDCS,38 which both applied individualised and tailored CT, and 
may therefore direct modulation of cortical areas or promote 
residual brain plasticity mechanisms related to specific cogni-
tive abilities. In addition, both studies selected the left DLPFC 
as the single target site, as clinical and experimental findings 
have uniformly indicated the critical role of the DLPFC in both 
‘cold’ (eg, working memory, inhibition and shifting) and ‘hot’ 
(eg, motivational, emotional or reward- based) executive func-
tions.39 Based on our findings, stimulating a single brain area 
(left DLPFC) with adjunctive tailored CT may be an effective 
protocol for enhancing compensatory mechanisms for a specific 
subdomain of cognitive dysfunction in MCI or AD.
Several limitations of the study should be considered. First, 
the overall ROB was 22.2% in the included studies, although 
the ROB was unclear for random sequence generation and allo-
cation concealment. Second, ctDCS showed efficacy for various 
outcomes, including immediate working memory, general cogni-
tion and working memory at 1- month follow- up. However, 
these findings were derived from a single study with small sample 
size (n=12).40 Third, we combined AD with MCI as our study 
subjects, which may increase the statistical power and generalis-
ability of our study findings. However, AD and MCI are distinct 
clinical stages of neurocognitive disorders, suggesting that 
these conditions may respond differently to treatment. Indeed, 
subgroup analysis of pure AD versus MCI subgroups revealed 
that only the population with AD responded positively to NIBS 
for general cognition. Finally, sham tDCS and sham rTMS were 
grouped based on the assumption that they would have similar 
placebo responses, despite the differences in the methods.
The present study is the first systematic review and NMA 
to investigate the effects of NIBS on cognition in individuals 
with AD or MCI, and to combine direct and indirect evidence 
to delineate the efficacy of head- to- head comparisons of rTMS 
versus tDCS with/without combining CT on cognitive functions. 
We also conducted component NMA to strengthen treatment 
evaluation and increase the precision for assessing component 
effects of complex interventions; thus, enhancing the utility of 
the results for clinical practice.
CONCLUSION
Our data suggest that HFrTMS is more effective than atDCS 
for improving global cognition, and patients with AD may have 
better responses to rTMS and tDCS than MCI. Combining CT 
with NIBS, particularly tailored CT and single stimulation site of 
left DLPFC, may be beneficial for specific cognitive subdomain. 
Sustained cognitive protective effects were observed at 1- month 
follow- up. Overall, NIBS is well tolerated.
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